GSA Capital Partners’s ALX Oncology ALXO Stock Holding History

GSA Capital Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$856K	Buy	413,545 +344,558	+499%	+$617K	0.05%	612
2026 Q1	$138K	Sell	68,987 -23,667	-26%	-$45.1K	0.01%	1524
2025 Q4	$105K	Buy	92,654 +4,489	+5%	+$6.8K	0.01%	1524
2025 Q3	$161K	Buy	88,165 +6,839	+8%	+$5.92K	0.01%	1470
2025 Q2	$34K	Buy	+81,326	New	+$41K	﹤0.01%	1677
2024 Q4	–	Sell	-48,204	Closed	-$88K	–	1576
2024 Q3	$88K	Buy	+48,204	New	+$179K	0.01%	1501
2024 Q2	–	Sell	-10,289	Closed	-$115K	–	1595
2024 Q1	$115K	Buy	+10,289	New	+$145K	0.01%	1476
2023 Q3	–	Sell	-12,730	Closed	-$96K	–	1465
2023 Q2	$96K	Buy	+12,730	New	+$83.3K	0.01%	1380
2022 Q4	–	Sell	-16,114	Closed	-$154K	–	1431
2022 Q3	$154K	Buy	+16,114	New	+$188K	0.02%	1289
2022 Q1	–	Sell	-24,203	Closed	-$520K	–	1377
2021 Q4	$520K	Buy	+24,203	New	+$1.04M	0.07%	574

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

GSA Capital Partners's ALXO Position: Q2 2026 in Review

GSA Capital Partners increased its ALX Oncology (ALXO) stake by 499% in Q2 2026, buying an estimated $617K and bringing the position to 413,545 shares worth $856K. The position accounts for 0.05% of the portfolio, ranked #612.

GSA Capital Partners first reported a position in ALXO in Q4 2021 and has held it in 10 quarters since. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

GSA Capital Partners held 413,545 shares of ALX Oncology worth $856K as of Q2 2026.
GSA Capital Partners bought 344,558 ALX Oncology shares in Q2 2026, an estimated $617K.
ALX Oncology made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #612 holding.
GSA Capital Partners first reported a position in ALX Oncology in Q4 2021 and has held it in 10 quarters since.
93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.